Regulation - CSL Behring

Filter

Current filters:

CSL Behring

Popular Filters

EMA approves fortnightly dosing option for CSL’s Hizentra

EMA approves fortnightly dosing option for CSL’s Hizentra

05-12-2013

Plasma-protein specialists CSL Behring, a subsidiary of Australia’s CSL Ltd (CSL: AX), announced today…

CSL BehringEuropeHizentraImmunologicalsPharmaceuticalRegulationUK

CSL Behring’s Hizentra approved in Japan for PID and SID

CSL Behring’s Hizentra approved in Japan for PID and SID

27-09-2013

The Japanese Ministry of Health, Labor and Welfare has approved Hizentra for the treatment of primary…

Asia-PacificCSL BehringHizentraImmunologicalsPharmaceuticalRare diseasesRegulation

CSL Behring's Berinert OKed in Europe for short-term prophylaxis in HAE

16-04-2013

Germany-based CSL Behring, a unit of Australia's CSL Ltd (ASX: CSL) says that European health authorities…

BerinertBiotechnologyCSL BehringCSL LimitedEuropeRare diseasesRegulation

CSL Behring gains expanded use for Corifact in USA

06-03-2013

Corifact, Factor XIII Concentrate (Human), to include the peri-operative management of surgical bleeding…

CorifactCSL BehringCSL LimitedNorth AmericaPharmaceuticalRare diseasesRegulation

Back to top